Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug ...
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...
Hosted on MSN1mon
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug NipocalimabA Precise and Powerful Mechanism Nipocalimab is a fully human monoclonal antibody that works by selectively binding to the neonatal Fc receptor (FcRn), disrupting the recycling of IgG antibodies.
IgY directed against conserved mammalian proteins is easier to produce than IgG because of the evolutionary distance between mammals and birds; and IgY does not bind to mammalian Fc receptors or ...
The shape of the IgE molecule differs dramatically from that of IgG. X-ray and nuclear magnetic ... high-affinity receptor FcεRI (high-affinity Fc receptor for IgE) on mast cells and antigen ...
S-1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies, and S-4321 is a non-depleting bifunctional PD‑1: FcγRIIb‑selective agonist antibody for the treatment of ...
Proteintech has designed recombinant antibodies featuring the company's FcZero backbone, engineered to silence the Fc domain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback